Mark Stephen Kindy
Executive Director, Center for Drug Discovery and Innovation
University of South Florida, USA
Department of Pharmaceutical Sciences
Dr. Mark Kindy is a biochemist/neuroscientist and Professor/Associate Dean for Research in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of South Florida and Senior Research Career Scientist at the James A. Haley VA Medical Center. He recently moved from the Department of Regenerative Medicine and Cell Biology and Neurosciences at the Medical University of South Carolina and a Senior Research Career Scientist/Deputy Associate Chief of Staff for Research at the Ralph H. Johnson VA Medical Center in Charleston, SC. He received his BS from the University of Massachusetts in Zoology and PhD from Boston University School of Medicine in Biochemistry. He was a postdoctoral fellow at the Salk Institute. Dr. Kindy started his faculty career at the University of Kentucky School of Medicine in the Department of Biochemistry and the Center on Aging. His area of expertise is neurodegenerative disorders, animal modeling, mechanisms associated with diseases and regeneration of the brain.
Amyloid formation and Alzheimer’s disease
Protein structure and function
George Perry, Ph.D.
Professor and Dean of College of Sciences
University of Texas at San Antonio, USA
Dr. George Perry received his PhD in Marine Biology from Scripps Institution of Oceanography, University of California at San Diego. He completed his Postdoctoral Fellowship in the Department of Cell Biology, Baylor College of Medicine, Houston, Texas.Dr. Perry joined the UTSA faculty in 2006 from Case Western Reserve University where he was Professor of Pathology and Neurosciences and Chair of the Department of Pathology. He is also distinguished as one of the top 20 Alzheimers disease researchers with over 800 publications, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in Free Radical research. He currently serves as and President for the American Association of Neuropathologists. He is on the editorial board of over 60 journals including American Journal of Pathology and Journal of Biological Chemistry, and is Editor-in-Chief of Journal of Alzheimer’s Disease.
Dr. Perry’s studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease. The lab has shown that oxidative damage is the initial cytopathology in Alzheimer disease. They are working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals. Current studies focus on the mechanism for RNA-based redox metal binding consequences of RNA oxidation on protein synthesis rate and fidelity role of redox active metals in mediating prooxidant and antioxidant properties signal transduction pathways altered in Alzheimer disease that allow neurons to evade apoptosis mechanism of phosphorylation control of oxidative damage to neurofilament proteins